科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02171 科济药业-B

休市中 05-22 16:08:22

17.510

+0.000

0.00%

最高18.200	最低17.300	成交量435.67万
今开17.400	昨收17.510	日振幅5.14%
总市值99.98亿	流通市值99.98亿	总股本5.71亿
成交额7,674万	换手率0.76%	流通股本5.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"科济药业-B","latestPrice":17.51,"timestamp":1779437302004,"preClose":17.51,"halted":0,"volume":4356674,"delay":0,"changeRate":0,"floatShares":571000000,"shares":571000000,"eps":-0.177264,"marketStatus":"休市中","change":0,"latestTime":"05-22 16:08:22","open":17.4,"high":18.2,"low":17.3,"amount":76739014,"amplitude":0.051399,"askPrice":17.52,"askSize":10000,"bidPrice":17.51,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.197261,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779759000000},"marketStatusCode":7,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":17.51,"openAndCloseTimeList":[[1779413400000,1779422400000],[1779426000000,1779436800000]],"volumeRatio":0.319606363386869,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171","defaultTab":"news","newsList":[{"id":"2636893927","title":"科济药业-B(02171)股东将股票由UBS Securities Hong Kong转入花旗银行 转仓市值4.32亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636893927","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636893927?lang=zh_cn&edition=full","pubTime":"2026-05-20 08:08","pubTimestamp":1779235706,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月19日，科济药业-B股东将股票由UBS Securities Hong Kong转入花旗银行，转仓市值4.32亿港元，占比4%。科济药业发布公告称，于5月15日与主要股东益杰生物技术(卖方)及联席配售代理订立协议，拟向不少于六名独立专业投资者以先旧后新方式配售2370万股，占扩大后股本约3.99%，每股作价19.84港元，较公司5月14日收市价21.92港元折让约9.49%，所得款项净额约为4.62亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2236285917.USD","LU1162221912.USD","LU1366192091.USD","LU0162691827.USD","LU0072461881.USD","BK4585","LU0098860793.USD","BK4534","LU0310800965.SGD","LU0170899867.USD","LU2462157665.USD","LU2125154778.USD","LU1668664300.SGD","BK4207","LU0314106906.USD","BK1585","LU0203347892.USD","LU0320765646.SGD","LU2417539215.USD","LU0106831901.USD","BK1161","LU0128525689.USD","LU1244550221.USD","BK1587","LU0980610538.SGD","BK1574","BK4588","LU1201861249.SGD","BK4566","LU1267930227.SGD","LU0648001328.SGD","LU2125154935.USD","02171","LU0130102774.USD","LU0130517989.USD","LU1791807156.HKD","BK4559","LU1244550494.USD","LU0477156953.USD","IE00BSNM7G36.USD","LU0203345920.USD","LU1244550577.SGD","LU1506573853.SGD","BK4504","LU2360032135.SGD","LU2456880835.USD","LU0052756011.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636046305","title":"港股异动 | 创新药概念股全线下挫 全球债市抛售潮初现 高利率或冲击行业估值及融资端","url":"https://stock-news.laohu8.com/highlight/detail?id=2636046305","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636046305?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:38","pubTimestamp":1779075485,"startTime":"0","endTime":"0","summary":"消息面上，霍尔木兹海峡持续封锁，正推动油价攀升至每桶105美元以上。全球债券市场抛售潮征兆已现。美国10年期国债收益率升至4.5%以上，日本30年期国债收益率首次突破4%，英国长期国债收益率则升至28年来的最高水平，引发市场对于未来全球金融环境趋紧的担忧。其中，4 月全球、美国、国内创新药投融资均呈现强劲复苏的态势。但也有分析人士指出，若全球利率环境进入更高水平且持续，将冲击创新药行业估值及融资端。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1574","BK4585","BK4588","BK1585","02137","09141","09939","VXUS","BK1587","09966","06978","02171","03141","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635720615","title":"科济药业-B(02171)股东将股票存入UBS Securities Hong Kong 存仓市值19.27亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635720615","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635720615?lang=zh_cn&edition=full","pubTime":"2026-05-15 08:15","pubTimestamp":1778804141,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月14日，科济药业-B(02171)股东将股票存入UBS Securities Hong Kong，存仓市值19.27亿港元，占比14.5%。科济药业-B发布公告，于2026年5月15日(交易时段前)，公司、卖方益杰生物技术控股有限公司及联席配售代理订立配售协议，据此，卖方同意出售，而联席配售代理同意担任卖方的代理，并基于最大努力促使不少于六名承配人以每股配售股份19.84港元的配售价购买不超过2370万股配售股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1585","BK1574","BK1161","BK1587","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635272710","title":"科济药业-B(02171)拟折让约9.49%先旧后新配股 净筹约4.62亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635272710","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635272710?lang=zh_cn&edition=full","pubTime":"2026-05-15 08:10","pubTimestamp":1778803826,"startTime":"0","endTime":"0","summary":"配售价为每股配售股份19.84港元，较股份于最后交易日在联交所所报收市价每股21.92港元折让约9.49%。假设除配发及发行认购股份以及配售股份悉数获配售外，公司已发行股本于本公告日期至认购事项完成期间并无变动，2370万股将予配售的现有股份占：公司于本公告日期之现有已发行股本约4.15%;及公司于紧随认购事项完成后经配发及发行认购股份扩大的已发行股本约3.99%。认购事项之所得款项总额及估计所得款项净额预计分别约为4.7亿港元及4.62亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1585","BK1161","BK1587","02171","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02171","81024","00719","09688","01548","01951","06186","02276","01905","01952","06049","06060","00013","00772","02126","06660","06609","09626","09888","03700","01833","09699","01357","02192","00762","01024","06969","02306","06160","06996","00169","01440","02618","02096","01783","02256","06963","09992","01060","02285","02013","00136","00909","02158","02197","02252","03692","02172","09858","03888"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135873113","title":"异动解读 | CAR-T研究成果获国际认可，科济药业-B盘中大涨6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135873113","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135873113?lang=zh_cn&edition=full","pubTime":"2026-05-13 09:43","pubTimestamp":1778636632,"startTime":"0","endTime":"0","summary":"科济药业-B今日盘中股价大幅上涨6.01%，引起了市场的高度关注。消息面上，公司近期接连披露了多项CAR-T细胞疗法的重要研究进展。此外，公司基于自主研发THANK-u Plus平台开发的两款通用型CAR-T细胞疗法——靶向BCMA的CT0596和靶向CD19/CD20的CT1190B的研究摘要，也已被欧洲血液学协会年会接受，并将进行壁报展示。这些研究成果获得国际顶级学术会议的认可，显著提升了市场对公司创新研发实力和未来商业化潜力的信心，被认为是推动股价上涨的主要动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115124148","title":"科济药业-B更新4月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1115124148","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115124148?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:36","pubTimestamp":1778146566,"startTime":"0","endTime":"0","summary":"2026年5月7日，科济药业控股有限公司发布截至2026年4月30日的股份变动月报表。公告显示，公司注册股本维持在200,000,000,000股普通股，面值每股0.00000025美元，总注册股本为50,000美元，较上月无变化。在已发行股份及库存股份方面，截至4月30日，科济药业-B已发行股份由3月底的570,352,999股增至570,942,748股，库存股份数维持在7,818,000股，合计发行股本由578,170,999股增加至578,760,748股，单月净增589,749股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633191971","title":"科济药业-B盘初涨超3% CT0596与CT1190B研究结果摘要已被EHA年会接受进行壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2633191971","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633191971?lang=zh_cn&edition=full","pubTime":"2026-05-06 09:47","pubTimestamp":1778032020,"startTime":"0","endTime":"0","summary":"　　科济药业-B盘初涨超3%，截至发稿，股价上涨1.90%，报21.50港元，成交额1947.27万港元。　　近日，科济药业-B发布公告，CT0596用于治疗复发╱难治性多发性骨髓瘤╱浆细胞白血病的IIT的研究结果摘要，及CT1190B用于治疗复发╱难治性B细胞非霍奇金淋巴瘤的IIT的研究结果摘要，已被2026年欧洲血液学协会年会接受进行壁报展示。　　CT0596是一款靶向BCMA的通用型CAR-T细胞疗法，基于科济药业自主研发的THANK-u Plus平台开发，目前正在R/R MM或PCL中开展IIT进行评估。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-05-06/doc-inhwxhnr3538418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02171","BK1161","BK1574","BK1585","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393819","title":"科济药业-B(02171)：CT0596及CT1190B的研究结果摘要已被2026年EHA年会接受以壁报展示呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393819","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630393819?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:05","pubTimestamp":1777287942,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B 发布公告，CT0596用于治疗复发╱难治性多发性骨髓瘤╱浆细胞白血病的IIT的研究结果摘要，及CT1190B用于治疗复发╱难治性B细胞非霍奇金淋巴瘤的IIT的研究结果摘要，已被2026年欧洲血液学协会年会接受进行壁报展示。摘要和进一步信息将于欧洲中部夏令时间2026年5月12日15:30后公布。CT0596显示出初步良好的安全性及令人鼓舞的疗效信号。本公司计划于2026年启动针对R/R MM和原发性浆细胞淋巴瘤的Ib期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1585","BK1587","BK1161","02171","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116699470","title":"异动解读 | 科济药业-B盘中大跌5.04%，前期利好兑现后股价连续回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1116699470","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116699470?lang=zh_cn&edition=full","pubTime":"2026-04-22 10:31","pubTimestamp":1776825083,"startTime":"0","endTime":"0","summary":"科济药业-B今日盘中大跌5.04%，报23.74港元/股，成交额约8073万港元。消息面上，科济药业此前因自主研发的舒瑞基奥仑赛注射液（satri-cel）研究成果在国际顶级医学期刊《柳叶刀》正式刊载，盘中一度大涨逾10%。该成果标志着公司在实体瘤CAR-T疗法领域取得重要突破。然而，利好消息兑现后，股价连续两个交易日回落，累计回吐前期涨幅。当前股价已回落至利好发布前水平附近，短期获利盘出清压力较为明显。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110240414","title":"异动解读 | 科济药业-B盘中大涨10.92%，CAR-T疗法研究成果登《柳叶刀》提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1110240414","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110240414?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:40","pubTimestamp":1776649210,"startTime":"0","endTime":"0","summary":"科济药业-B今日盘中大涨10.92%，引起了市场的广泛关注。消息面上，公司自主研发的舒瑞基奥仑赛注射液（satri-cel）研究成果于近日在国际顶级医学期刊《柳叶刀》正式刊载，标志着公司在实体瘤CAR-T疗法领域取得重要突破。实体瘤CAR-T治疗长期被视为行业难点，此次研究成果获权威期刊认可，显著提升了市场对其核心管线商业化前景的预期。此外，近期诺和诺德与OpenAI达成战略合作，AI赋能创新药研发的利好情绪持续发酵，港股创新药板块整体表现活跃，亦对公司股价形成板块层面的支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146821480","title":"异动解读 | 诺和诺德联手OpenAI提振板块，科济药业-B盘中大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146821480","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146821480?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:06","pubTimestamp":1776233215,"startTime":"0","endTime":"0","summary":"科济药业-B今日盘中大涨5.07%，表现引人注目。消息面上，全球制药巨头诺和诺德宣布与人工智能领军企业OpenAI建立战略合作伙伴关系。此次合作旨在运用先进的人工智能能力分析复杂数据集，筛选具有潜力的候选药物，从而显著缩短从基础研究到惠及患者所需的时间。这一重磅消息提振了市场对AI赋能生物医药行业的整体信心。在此背景下，港股创新药板块今日表现活跃，科济药业-B作为板块内公司之一，股价也随之受到提振。多家券商指出，AI+生物医药应用前景广阔，有望成为AI技术率先落地的领域之一，并持续看好相关赛道的投资机会。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136591998","title":"科济药业-B2025年收入增至1.26亿元，CAR-T核心管线推动亏损显著收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1136591998","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136591998?lang=zh_cn&edition=full","pubTime":"2026-04-10 21:09","pubTimestamp":1775826551,"startTime":"0","endTime":"0","summary":"科济药业-B在截至2025年12月31日止年度实现收入约1.26亿元人民币，主要来自自体BCMA CAR-T细胞产品赛他泽的商业化销量增长。整体而言，科济药业-B在2025年度通过加强CAR-T产品商业化和高效管控，使收入明显增长、亏损幅度显著收窄，并在多靶点管线与通用型CAR-T平台上取得临床进展，彰显了细胞免疫疗法在血液和实体肿瘤领域的持续潜力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162990917","title":"科济药业-B更新3月股份变动月报表，股本增至578,170,999股","url":"https://stock-news.laohu8.com/highlight/detail?id=1162990917","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162990917?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:50","pubTimestamp":1775731853,"startTime":"0","endTime":"0","summary":"2026年4月9日，科济药业控股有限公司发布截至2026年3月31日的股份变动月报表。公告显示，公司法定股本数额维持在50,000美元，未发生增减变动。公司已发行股份由上月末的570,312,499股增加至570,352,999股，库存股份维持7,818,000股不变，当月合计新增40,500股，期末股份总数增至578,170,999股。新增部分主要来自首次公开发售后购股权计划的行使及2019年股权激励计划。截至月末，该计划所对应尚可行使或转让的股份总数为18,664,415股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618604733","title":"港股异动 | 科济药业-B(02171)再涨超12% 全年收入同比增超2倍 昨日起正式进入港股通名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2618604733","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618604733?lang=zh_cn&edition=full","pubTime":"2026-03-10 10:20","pubTimestamp":1773109241,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B再涨超12%，截至发稿，涨10.78%，报15.42港元，成交额1.27亿港元。消息面上，3月6日，科济药业发布年度业绩，收益1.26亿元人民币，同比增长218.7%；母公司拥有人应占亏损9786.1万元，同比收窄87.7%。值得注意的是，3月9日，科济药业正式获纳入港股通名单。本次纳入体现了市场对公司核心CAR-T业务发展潜力、经营规范性及股份流动性的认可，符合公司长期发展战略及全体股东的根本利益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02171","BK1587","BK1161","VXUS","BK4588","BK4585","BK1585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156391493","title":"异动解读 | 获纳入港股通及业绩改善，科济药业-B盘中大涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156391493","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156391493?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:36","pubTimestamp":1773106618,"startTime":"0","endTime":"0","summary":"科济药业-B今日盘中大幅上涨5.32%，引起了市场的广泛关注。消息面上，科济药业近期获重新纳入港股通标的，此举预计将吸引更多内地投资者，提升股票的流动性与市场关注度。同时，公司披露的2025年年报显示业绩显著改善，亏损额大幅收窄，增强了投资者信心。具体而言，公司的BCMA CAR-T产品泽沃基奥仑赛注射液在2025年实现销售额1.26亿元，并通过与华东医药的合作有效控制了销售成本。此外，科济药业拥有国内CAR-T领域最丰富的在研管线之一，包括接近上市的CLDN18.2 CAR-T及多款处于临床早期的通用型CAR-T产品，展现了强大的长期研发潜力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618627333","title":"科济药业-B(02171.HK)授出426.7万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2618627333","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618627333?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:37","pubTimestamp":1773067022,"startTime":"0","endTime":"0","summary":"格隆汇3月9日丨科济药业-B(02171.HK)宣布，于2026年3月9日，公司根据首次公开发售后购股权计划的条款向181名购股权承授人授出426.7万份购股权，惟须待购股权承授人接纳后方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260309/32055246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK1587","BK1574","02171","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618603965","title":"科济药业2025：亏损收窄87%，实体瘤CAR-T冲刺上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2618603965","media":"药智网","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618603965?lang=zh_cn&edition=full","pubTime":"2026-03-09 15:19","pubTimestamp":1773040781,"startTime":"0","endTime":"0","summary":"2025年，科济药业实现收益约1.26亿元，这一增长主要来源于其核心商业化产品赛恺泽的销售。2025年，科济药业净亏损收窄至约1.03亿元，较2024年的7.98亿元大幅减少约6.95亿元，同比收窄87.09%。现金流方面，截至2025年12月31日，公司现金及现金等价物约为11.23亿元。赛恺泽作为全人源BCMA靶向自体CAR-T细胞产品，2025年商业化进程全面加速。研发管线方面，科济药业2025年取得多项里程碑式进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030915325297aae146&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030915325297aae146&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1161","BK1585","BK1574","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618618185","title":"科济药业-B绩后大涨超32% 年度股东应占亏损同比收窄87.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618618185","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618618185?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:37","pubTimestamp":1773020220,"startTime":"0","endTime":"0","summary":"　　科济药业-B绩后大涨逾32%，截至发稿，股价上涨32.48%，现报14.40港元，成交额4770.84万港元。　　3月6日，科济药业-B发布截至2025年12月31日止年度业绩，收益1.26亿元，同比增长218.7%；母公司拥有人应占亏损9786.1万元，同比收窄87.7%；每股基本亏损0.18元。截至2025年12月31日止年度，集团的收益主要来自赛恺泽 ，其中赛恺泽的主要收益乃以出厂价格而非终端市场价进行计算的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-09/doc-inhqizzp6892836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","02171","BK1585","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123441748","title":"异动解读 | 科济药业-B纳入港股通，盘中大涨15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123441748","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123441748?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:31","pubTimestamp":1773019900,"startTime":"0","endTime":"0","summary":"科济药业-B(02171)今日盘中大涨15%，引起了市场的广泛关注。消息面上，公司股票被纳入沪港通及深港通南向交易的合资格股票名单（港股通），自今日起正式生效。此次纳入体现了市场对公司核心CAR-T业务发展潜力、经营规范性及股份流动性的认可，预计将吸引更多内地投资者，显著提升市场关注度和流动性。纳入港股通后，符合条件的中国内地投资者可通过上海证券交易所及深圳证券交易所港股通交易系统，直接买卖公司在香港联合交易所有限公司上市的股份，这为公司资本市场发展注入了强劲动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":-0.1121},{"period":"1month","weight":-0.2812},{"period":"3month","weight":0.121},{"period":"6month","weight":0.0349},{"period":"1year","weight":-0.2286},{"period":"ytd","weight":0.1791}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0153},{"period":"1year","weight":0.0876},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"科济药业控股有限公司是一家主要从事探索、研发细胞疗法的投资控股公司。该公司的主营业务是从事开发嵌合抗原受体T细胞（CAR-T）细胞疗法，以满足临床需求，包括但不限于血液恶性肿瘤、实体瘤及自身免疫性疾病。该公司的主要产品包括赛恺泽（泽沃基奥仑赛注射液）、舒瑞基奥仑赛注射液、通用型CAR-T细胞产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.07858},{"month":2,"riseRate":0.6,"avgChangeRate":0.230493},{"month":3,"riseRate":0.2,"avgChangeRate":-0.058535},{"month":4,"riseRate":0.4,"avgChangeRate":-0.02351},{"month":5,"riseRate":0.6,"avgChangeRate":0.030294},{"month":6,"riseRate":0.5,"avgChangeRate":0.033426},{"month":7,"riseRate":0.4,"avgChangeRate":-0.015336},{"month":8,"riseRate":0.6,"avgChangeRate":0.066197},{"month":9,"riseRate":0.4,"avgChangeRate":0.033481},{"month":10,"riseRate":0.6,"avgChangeRate":0.024843},{"month":11,"riseRate":0.6,"avgChangeRate":0.051023},{"month":12,"riseRate":0.4,"avgChangeRate":-0.058482}],"exchange":"SEHK","name":"科济药业-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科济药业-B,02171,科济药业-B股票,科济药业-B股票老虎,科济药业-B股票老虎国际,科济药业-B行情,科济药业-B股票行情,科济药业-B股价,科济药业-B股市,科济药业-B股票价格,科济药业-B股票交易,科济药业-B股票购买,科济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}